-Shares of BriaCell Therapeutics Corp. BCTX, 111.64% more than doubled Wednesday on heavy volume, after the biotechnology company provided upbeat update on its breast cancer treatment.
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
๋ฉด์ฑ ์ฌํญ
ํด๋น ์ ๋ณด์ ๊ฒ์๋ฌผ์ ๊ธ์ต, ํฌ์, ํธ๋ ์ด๋ฉ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ์ฅ ์ฌํญ์ผ๋ก ๊ฐ์ฃผ๋์ง ์์ผ๋ฉฐ, ํธ๋ ์ด๋ฉ๋ทฐ์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ฒ์ด ์๋๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ์กฐํ์ธ์.
๋ฉด์ฑ ์ฌํญ
ํด๋น ์ ๋ณด์ ๊ฒ์๋ฌผ์ ๊ธ์ต, ํฌ์, ํธ๋ ์ด๋ฉ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ์ฅ ์ฌํญ์ผ๋ก ๊ฐ์ฃผ๋์ง ์์ผ๋ฉฐ, ํธ๋ ์ด๋ฉ๋ทฐ์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ฒ์ด ์๋๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ์กฐํ์ธ์.